-The Telegraph New Delhi: The government's price cap on coronary stents has not deterred the health-care industry from continuing to offer hospitals profit opportunities of tens of thousands of rupees on other kinds of stents, concerned doctors and health-care industry representatives said.     The National Pharmaceutical Pricing Authority (NPPA), the government's price regulator, had on February 15 imposed a cap of about Rs 30,000 on coronary stents. But hospitals can continue to...

-The Indian Express He added that the amendment means that companies are not required now to show the names of political parties they have contributed to. Chandigarh: Chief Election Commissioner Nasim Zaidi on Saturday said that amendments to the Companies Act of 2013, removing cap on corporate contribution to political parties, are “basically hitting” transparency in funding. “Two things are likely to happen in future. There would be less and less...

-The Hindu Business Line Frowns on India’s IP laws; New Delhi unfazed, says laws are TRIPS-compliant New Delhi: Expressing its disappointment with India for not making adequate changes in its IP laws and regulations despite announcing its National IPR policy last year, the US Trade Representative’s (USTR) office has once again placed the country in the ‘priority watch’ list in this year’s edition of the Special 301 report. “Almost a year after the...

-The Hindu We need a legal mechanism to ensure that all generics are of the same standard as the innovator product The Prime Minister’s recent announcement on making it mandatory for doctors to prescribe only the generic name, and not brand name of a drug, has led to a flutter. If enacted, the move will make it illegal for Indian doctors to write out a prescription for the trademark of the drug,...

-The Times of India NEW DELHI: The government has invoked special powers under the law to prohibit stent makers from withdrawing their products from the market for the next six months. Amid reports that several manufacturers, including Abbott and Medtronic, are seeking to withdraw premium, high-priced stents from the Indian market on account of the price cap imposed by National Pharmaceutical Pricing Authority (NPPA), the government has directed companies to maintain production,...